Lipid nanoparticle (LNP)-mediated mRNA delivery to brain tumors is limited by the blood-brain barrier (BBB) and lack of active tumor targeting. Glucose transporter 1 (GLUT1), abundant on brain endothelium and overexpressed in glioblastoma, offers a single target for both BBB transcytosis and preferential tumor uptake. However, effective GLUT1 engagement requires high ligand densities on LNPs to compete with blood glucose, a threshold unattainable through conventional PEG-lipid functionalization. Furthermore, incorporating hydrophilic sugar ligands (e.g., glucose, mannose) can disrupt LNP architecture and mRNA encapsulation. Here, mannose-cholesterol LNPs (MC_LNPs) are developed to target GLUT1 and overcome these challenges. Mannose-cholesterol conjugation achieves ∼30 mol% surface ligand density, and incorporating positively charged DC-cholesterol restores >90% mRNA encapsulation. In healthy mice, MC_LNPs achieve 9.9-fold greater brain accumulation than non-targeted formulations, confirming BBB penetration. Functional delivery is validated using Cre mRNA in Ai14 reporter mice, revealing expression in neurons and astrocytes. In orthotopic glioblastoma models, phosphatase and tensin homolog (PTEN) mRNA-loaded MC_LNPs exhibit preferential tumor accumulation, restoring tumor suppression, reducing tumor burden 6-fold, and extending median survival from 33 to 49 days. MC-LNPs represent the first dual-targeted mRNA platform for brain tumors, establishing cholesterol-based functionalization as a strategy to achieve high ligand densities for efficient transporter/receptor targeting.